C2N Diagnostics

C2N Diagnostics, established in 2007 and headquartered in the United States, is a biotechnology startup making significant strides in the medical industry. The company's dedication to innovation and excellence has been acknowledged by Fierce Medtech, which named C2N one of its Fierce 15 for 2020, recognizing it as "one of the most promising private companies in the industry." C2N Diagnostics is committed to bringing Clarity Through Innovation™ to the forefront of therapeutic discovery and diagnostics for human neurological disorders. Its flagship product, the PrecivityAD™ blood test, employs mass spectrometry to measure multiple analytes in the blood, including Aβ42, Aβ40, and apolipoprotein E isoforms. While not a standalone diagnostic tool for Alzheimer's disease, it serves as a crucial aid for physicians in the evaluation process, predicting brain amyloid plaques as determined by PET scan results. Notably, the test has received a Breakthrough Device Designation from the U.S. Food and Drug Administration and has achieved the CE Mark from the European Union. C2N's steadfast commitment to advancing brain health monitoring through accessible and cost-effective blood tests has not gone unnoticed. In March 2024, the company secured a remarkable $15.00M corporate round investment from Eisai US, endorsing its pioneering efforts in revolutionizing neurological disorder diagnostics and therapeutic discovery. For further details, visit www.C2N.com.